Pancreatic Metastasis From Renal Cell Carcinoma: Which Patients Benefit From Surgical Resection?

Authors: Zerbi, Alessandro1; Ortolano, Enrico2; Balzano, Gianpaolo2; Borri, Anna3; Beneduce, Aldo2; Di Carlo, Valerio2

Source: Annals of Surgical Oncology, Volume 15, Number 4, April 2008 , pp. 1161-1168(8)

Publisher: Springer

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Pancreas is a possible site of metastases from renal cell carcinoma (RCC). The aim of this study was to define the role of surgery in their treatment.

We retrospectively analyzed 36 patients with pancreatic metastasis from RCC observed between January 1998 and February 2006. Patients were categorized into three risk groups according to the modified Memorial Sloan-Kettering prognostic factors model.

Resective surgery was performed in 23 patients, as follows: 11 distal pancreatectomy, 5 enucleation, 4 pancreatoduodenectomy, 2 total pancreatectomy, and 1 middle pancreatectomy. No perioperative mortality was observed; the morbidity rate was 47.8%. All patients who underwent resection belonged to the favorable risk group. Surgical resection was excluded in 13 cases because of locally advanced disease (2 cases) or extrapancreatic disease (11 cases); 5 of these patients were at favorable, 7 at intermediate, and 1 at poor risk. In patients undergoing surgery, the 5-year actuarial survival rate was 88%, and median disease-free survival was 44 months. Patients who did not undergo surgery had a 5-year survival rate of 47%, with a median survival time of 27 months (P = .02).

Patients with pancreatic metastases from RCC belonging to a favorable risk group are candidates for resection, even in the presence of another metastatic site or multifocal pancreatic disease.

Keywords: Renal cell carcinoma; Pancreatic metastases; Pancreatic resection; Pancreas

Document Type: Research article

DOI: 10.1245/s10434-007-9782-0

Affiliations: 1: Pancreas Unit, Department of Surgery, S. Raffaele Scientific Institute, V. Olgettina 60, 20132, Milan, Italy, Email: zerbi.alessandro@hsr.it 2: Pancreas Unit, Department of Surgery, S. Raffaele Scientific Institute, V. Olgettina 60, 20132, Milan, Italy 3: Department of Oncology, S. Raffaele Scientific Institute, V. Olgettina 60, 20132, Milan, Italy

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$47.00 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A